Ziresovir

PreclinicalSmall molecule

SShanghai Ark Biopharmaceutical Co., Ltd.

Ziresovir is one of 5 small molecule programs targeting Respiratory Syncytial Virus Infections. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Syncytial Virus InfectionsRecruiting

Respiratory Syncytial Virus InfectionsPreclinical

Recruiting

Competition

Competitive Landscape

4 competitors in Respiratory Syncytial Virus Infections

#DrugCompanyPhaseTrials

Rsvpref3 Vaccine

GSK

Phase 3

4 2

Rsvpref3 OA Investigational Vaccine

GSK

Phase 3

2 3

Rsvpref3 OA Vaccine

GSK

Phase 3

2 4

Adjuvanted Rsvpref3 Vaccine

GSK

Phase 2

1 5

Ziresovir

SShanghai Ark Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

PreclinicalRecruiting

Respiratory Syncytial Virus Infections

NCT07658534

Clinical

Trials by Indication[1]

Tics1 trial

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

Completed·SShanghai Ark Biopharmaceutical Co., Ltd.·Phase 1·NCT04788017·24 enrolled

Respiratory Syncytial Virus Infections1 trial

A Randomized, Double-blind, Two-stage, Placebo-controlled Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of Ziresovir (AK0529) in Adult Patients at High Risk for Respiratory Syncytial Virus (RSV) Infection.

Recruiting·SShanghai Ark Biopharmaceutical Co., Ltd.·Preclinical·NCT07658534·290 enrolled

Unspecified1 trial

A Single-Center, Randomized, Partially Double-Blind, Placebo- and Active-Controlled, Four-period Crossover, Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

Completed·SShanghai Ark Biopharmaceutical Co., Ltd.·Phase 1·NCT06591845·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Ziresovir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ziresovir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ziresovir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Ark Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai Ark Biopharmaceutical Co., Ltd.

Ziresovir

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Tics1 trial

Respiratory Syncytial Virus Infections1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News